This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Gilead Increases Enrollment Target, Pharma Rally Continues
by Ritujay Ghosh
Substantial progress has been made over the past few weeks with pharmaceutical companies speeding up development of coronavirus vaccines.
Gilead Brings Likely Coronavirus Cure, Pharma Rallies on R&D
by Ritujay Ghosh
Shares of Gilead Science Inc. (GILD) rally on media reports that severe coronavirus patients were responding positively to the company's experimental treatment, remdesivir.
Microsoft (MSFT) Partners GE Healthcare to Fight Coronavirus
by Zacks Equity Research
Microsoft (MSFT) inks deal with GE Healthcare to roll out patient monitoring software with an aim to limit COVID-19 exposure for medical staff and conserve PPEs.
Pharma Stocks Rally on Sanofi, GSK Coronavirus Vaccine Tie-Up
by Ritujay Ghosh
If successful, the Sanofi (SNY) and GlaxoSmithKline plc (GSK) vaccine would be available in the second half of 2021. Shares of drugmakers jumped on the news.
Pharma Coronavirus Efforts Continue, Amgen & Incyte Join In
by Kinjel Shah
Amgen (AMGN) signs a deal with Adaptive Biotechnologies to discover antibodies to prevent/treat COVID-19. Incyte/Novartis (NVS) plan to initiate study on Jakafi for COVID-19- associated cytokine storm.
Tech Giants Boost Efforts to Deal With Coronavirus Crisis
by Radhika Pujara
Here we discuss how tech giants including Microsoft (MSFT) and others are leaving no stone unturned to address COVID-19 crisis in innovative ways, backed by AI, ML and cloud computing capabilities.
Microsoft, Adaptive Biotech Collaborate to Fight COVID-19
by Zacks Equity Research
Microsoft (MSFT) extends partnership with Adaptive Biotechnologies on an open source dataset to aid the development of a diagnostic vaccine for COVID-19.
What's in Store for Tenet Healthcare's (THC) Q4 Earnings?
by Zacks Equity Research
Tenet Healthcare's (THC) Q4 results are likely to reflect higher revenues, aided by its Hospital and Other Operations as well as Ambulatory segments, partly offset by lower admissions.
MEDNAX (MD) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Mednax's (MD) Q4 results reflect growth in same unit revenues and lower general and administrative expenses.
Why Earnings Season Could Be Great for Adaptive (ADPT)
by Zacks Equity Research
Adaptive (ADPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Top Ranked Momentum Stocks to Buy for December 30th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 30th
Adaptive Biotechnologies Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Adaptive Biotechnologies.
4 Biotech Stocks That Could Keep Beating Wall Street
by Zacks Equity Research
The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.
Illumina (ILMN) Inks Deal to Commercialize NGS-Based IVD Kits
by Zacks Equity Research
Illumina (ILMN) aims to expand access to NGS-based IVD test kits and improve patient outcomes through the new partnership deal.
Illumina (ILMN) Inks Deal to Develop Distributable Test Kits
by Zacks Equity Research
Illumina (ILMN) aims to expand access to genomic-based testing and improve patient outcome through the new partnership deal.
Do Options Traders Know Something About Adeptus Health (ADPT) Stock We Don't?
by Zacks Equity Research
Adeptus Health (ADPT) warrants investors' attention based on moves in the options market lately.
Adeptus Health (ADPT) Shares Continue to Fall: Here's Why
by Zacks Equity Research
Shares of Adeptus Health, Inc. (ADPT) have been severely underperforming. This is evidenced by the fact that the stock has lost 85.7% year to date
Why These 3 Healthcare Stocks Lost Half Their Value in November
by Supriyo Bose
As the equity market braced itself for the Trump era, some healthcare stocks felt the tremors of his ensuing policy reforms and declined significantly in November.
Bull of the Day: Adeptus Health (ADPT)
by Kevin Cook
Emergency healthcare has an aggressive player growing at high double-digits in just 4 states
4 Impressive Stocks Blowing Away Expectations
by Jeremy Mullin
First quarter earnings season has been a disappointment - but not for these four companies.